Prognostic and predictive significance of p53 mutation in aggressive B-cell lymphoma

International Journal of Hematology

Volumn 71, Issue 3, 2000, Pages 211-220

  Ichikawa, Atsushi ^a  

^a Department of Hematological Oncology   (Japan)

Author keywords

Aggressive B cell lymphoma; P53 mutation; Prognosis

Indexed keywords

PROTEIN P53;

B CELL LYMPHOMA; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MUTATION; PHYSIOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; REVIEW; TUMOR SUPPRESSOR GENE;

GENES, P53; HUMANS; LYMPHOMA, B-CELL; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034167651     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD.Ann Intern Med. 1986;104:757-765.
2. Laurence J, Coleman M, Alien SL, Silver RT, Pasmantier M. Combination chemotherapy of advanced diffuse histiocytic lymphoma with six-drug COP-BLAM regimen. Ann Intern Med. 1982;97:190-195.
3. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med. 1985;102:596-602.
4. Longo DL, DeVita VT Jr, Duffey PL, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991;9:25-38.